微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Modified FOLFOX6
Modified FOLFOX6

肿瘤

关键词肿瘤 治疗方法 结直肠癌

词汇介绍

拓展阅读

解析

Modified   英 /ˈmɒdɪfaɪd/   美 /mɑdəˌfaɪd/

释    义   adj. 改进的,修改的;改良的;v. 修改;缓和(modify的过去分词)

同根词   modifiable adj. 可修饰的;可更改的

               modification n. 修改,修正;改变

               modify vi. 修改

               modify vt. 修改,修饰;更改

例    句   At the other end of the spectrum of possibilities, the team modified all of the end dates after each iteration started. 在这个可能值范围的另一个端点,这个团队在每次迭代开始后,修改了所有迭代的终止日期。

 

FOLFOX6

释    义   n. 胃肠道肿瘤常用的化疗方案

例    句   To study the effect of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction neoadjuvant chemotherapy prior to standard chemoradiotherapy and total mesorectal excision (TME) surgery in patients with high-risk rectal adenocarcinoma. 研究阿柏西普联合改良氟尿嘧啶、亚叶酸钙和奥沙利铂(mFOLFOX6)在标准放化疗和全肠系膜切除(TME)手术前对高危直肠腺癌患者进行新辅助化疗的效果。

概述

结直肠癌FOLFOX方案的经典药物包括氟尿嘧啶(5-Fu)、亚叶酸钙(甲酰四氢叶酸钙、CF、LV)和奥沙利铂(Oxaliplatin、L-OHP、OXA、乐沙定)。FOLFOX是以FOLFUHD方案为基础的,目前有FOLFOX1、FOLFOX2、FOLFOX3、FOLFOX4、FOLFOX5、FOLFOX6、FOLFOX7和mFOLFOX方案。FOLFOX1方案:OXA 130 mg/m2 IV gtt 2h d1,CF 500 mg/m2 IV gt

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial复制标题

Aflibercept联合改良FOLFOX6诱导化疗在标准放化疗和手术治疗高危直肠腺癌患者中的作用: GEMCAD 1402随机临床试验

发表时间:2019-08-29

影响因子:22.4

作者: Carlos Fernández-Martos

期刊:JAMA Oncol

IMPORTANCE: Preclinical studies suggest that a vascular endothelial growth factor (VEGF) blockade may play a role in the preoperative treatment of rectal adenocarcinoma; however, how to combine anti-VEGF drugs with neoadjuvant chemotherapy (CT) and/or chemoradiotherapy (CRT) remains controversial. OBJECTIVE: To study the effect of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction CT prior to standard CRT and total mesorectal excision (TME) surgery in patients with high-risk rectal adenocarcinoma. DESIGN, SETTING, AND PARTICIPANTS: In the Grupo Español Multidisciplinar En Cancer Digestivo (GEMCAD) 1402 phase 2 randomized clinical trial, 180 patients aged 18 to 75 years, identified by centrally reviewed magnetic resonance imaging to have mrT3c-d/T4/N2 rectal adenocarcinoma, were enrolled from 20 treatment centers in Spain between January 2015 and March 2017. Patients were randomized in a 2:1 treatment to control arm ratio. The primary end point was evaluated at 2 interim and 1 final analyses. The study was designed to perform hypothesis testing at α = 2 and β = 2. A 2-sided P value of <1984 in the final analysis of the intention-to-treat population was the threshold for considering the experimental treatment to be more effective than the control.

译文

重要:临床前研究表明,血管内皮生长因子(VEGF)的阻断可能在直肠腺癌的术前治疗中发挥作用。然而,如何将抗VEGF药物与新辅助化疗(CT)和/或放化疗结合(CRT)仍存在争议。目的:研究阿柏西普联合改良氟尿嘧啶,亚叶酸和奥沙利铂(mFOLFOX6)诱导CT在标准CRT和全直肠系膜切除术(TME)手术前对高危直肠腺癌患者的疗效。设计,地点和参与者:在GrupoEspañol癌症消化道多学科(GEMCAD)1402 2期随机临床试验中,对180例年龄在18至75岁的患者进行了中央回顾性磁共振成像检查,确定其患有mrT3c-d / T4 / N2直肠在2015年1月至2017年3月期间,从西班牙的20个治疗中心招募了腺癌。将患者按2:1的治疗与对照组进行随机分组。在2个中期分析和1个最终分析中评估了主要终点。本研究旨在在α= 2和β= 2进行假设检验。对意向性治疗人群进行最终分析时,2侧P值<1984是认为实验治疗更有效的门槛比控制。